

Friday, March 8, 2024

Conference Center - Ground Floor

12:00 – 13:30	<b>Registration and Welcome Coffee</b>
13:30	<b>Welcome and introductory remarks</b> <i>E Zucca</i>
	<b>Marginal Zone Lymphoma (MZL)</b>
	Part 1- Chair: <i>AJM Ferreri</i>
	<b>Educational Lecture 1</b>
13:40 – 14:20	Nodal Marginal Zone Lymphoma <i>L Quintanilla-Fend</i>
14:20 – 14:40	Mechanism of Marginal Zone L treatment resistance: preclinical data <i>F Bertoni</i>
14:40 – 16:10	<b>Updates on the IELSG Studies</b>
14:40 – 15:00	IELSG44 – PIMENTO - FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis <i>L Ceriani</i>
15:00 – 15:10	IELSG46 – Integrated molecular and clinical profiling to optimize outcome prediction in splenic marginal zone lymphoma: Update on the digital pathology review <i>M Ponzoni</i>
15:10 – 15:30	IELSG47 – MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphoma <i>C. Thieblemont &amp; M Callanan</i>
15:30 – 15:40	IELSG48 – RITZ - Phase III, interventional, multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma <i>MC Piroso</i>
15:40 – 16:00	IELSG49 – Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas <i>A Stathis</i>
16:00 – 16:10	IELSG52 – Integrated molecular and clinical profiling to improve disease characterization and outcome prediction in nodal marginal zone lymphoma <i>MC Piroso</i>
16:10 – 16:40	<b>Coffee Break</b>
	Part 2 – Chair: <i>G. Nowakowski</i>
	<b>Educational Lecture 2</b>
16:40 – 17:20	T-cell redirecting therapies in MZL <i>G Iacoboni</i>
17:20 – 18:50	<b>IELSG Studies in the Pipeline</b>
17:20 – 17:40	IELSG53 – Phase III randomized study comparing targeted immunotherapy to rituximab plus chemotherapy in previously untreated, symptomatic MZL <i>A Conconi</i>
17:40 – 18:00	IELSG54 - Retrospective molecular study on transformed SMZL <i>E Cappello</i>
18:00 – 18:30	<b>MSK Collaboration</b> A Phase III trial of an early response-guided, staged approach for potentially curable indolent B-cell lymphomas <i>J Yahalom</i>
18:30 – 19:00	<b>A Pharma Study on Imaging in MZL</b> CXCR4 based Imaging in MZL: A phase III clinical trial to test [68Ga]Ga-PentixaFor versus [18F]FDG PET/CT imaging in MZL. <i>C Buske</i>
	<b>NK/T-cell Lymphoma</b>
19:00 – 19:20	IELSG50 – Pembrolizumab and radiotherapy for previously untreated patients with limited-stage NK/T cell lymphoma <i>S Cheng</i>
20:00	<b>Dinner</b>

Closed Meeting Saturday, March 9 2024  
07:00 – 08:00 IELSG Board of Directors

Sala Camino

Saturday, March 9, 2024

Conference Center Ground Floor

	<b>IELSG Study Discussion</b>
	Chair: <i>C Thieblemont</i>
	<b>Primary Mediastinal Lymphoma B-Cell Lymphoma (PBMCL)</b>
08:30 – 08:50	Clinical utility of Ct-DNA – Preliminary results of a Rouen/IOR study <i>V Camus</i>
08:50 – 09:10	The potential of radiomic analysis <i>L Ceriani</i>
09:10 – 09:30	Meta-analysis of frontline immunochemotherapy <i>A Dabrowska</i>
09:30 – 09:50	IELSG51 – Prior proposal for a future IELSG study in PMBCL <i>A Stathis</i>
09:50 – 10:10	Study proposal: Single-arm registry of patients with DS4 observed with repeated PET <i>D Hodgson</i>
	<b>Primary and Secondary Diffuse Large B-Cell Lymphoma of the Central Nervous System (CNS)</b>
	<b>Educational Lecture 3</b>
10:10 – 10:50	Vitreoretinal lymphoma <i>F Fend</i>
10:50 – 11:00	CNS Studies <i>AJM Ferreri</i>
11:00 – 12:00	<b>General Assembly</b> <b>IELSG MEMBERS ONLY</b>
	Chair: <i>F Cavalli</i>
	Discussion of administrative issues
12:00	<b>Closing Remarks</b>

Thank you very much to all our sponsors for supporting this event.

GOLD



SILVER



BRONZE



IELSG Annual Meeting 2024  
March 8-9, 2024 – Stresa (Italy)

Hotel La Palma  
Conference Center – Gardenia Hall  
Corso Umberto I n. 33 - 28838 Stresa



**INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP**  
Foundation for the Institute of Oncology Research  
Via Vincenzo Vela, 6 | CH-6500 Bellinzona  
Phone +41 58 666 73 21 | E-mail [ielsg@ior.usi.ch](mailto:ielsg@ior.usi.ch) | [www.ielsg.org](http://www.ielsg.org)